A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia.
Fiche publication
Date publication
mars 2016
Journal
Clinical lymphoma, myeloma & leukemia
Auteurs
Membres identifiés du Cancéropôle Est :
Dr LIOURE Bruno
Tous les auteurs :
Kantarjian HM, Lioure B, Kim SK, Atallah E, Leguay T, Kelly K, Marolleau JP, Escoffre-Barbe M, Thomas XG, Cortes J, Jabbour E, O'Brien S, Bories P, Oprea C, Hatteville L, Dombret H
Lien Pubmed
Résumé
Long-term disease-free survival in adult patients with acute lymphoblastic leukemia (ALL) remains unsatisfactory, and the treatment options are limited for those patients with relapse or a failure to respond after initial therapy. We conducted a dose-escalation/expansion phase II, multicenter, single-arm study to determine the optimal dose of coltuximab ravtansine (SAR3419), an anti-CD19 antibody-drug conjugate, in this setting.
Mots clés
Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, administration & dosage, Antineoplastic Agents, administration & dosage, Drug Resistance, Neoplasm, Female, Humans, Immunotoxins, administration & dosage, Male, Maytansine, administration & dosage, Precursor Cell Lymphoblastic Leukemia-Lymphoma, drug therapy, Recurrence, Retreatment, Treatment Outcome
Référence
Clin Lymphoma Myeloma Leuk. 2016 Mar;16(3):139-45